CRYOPORT INC (CYRX)
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Sector: Health Care
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
Director information for CYRX
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| CYRX | Chair of the Board of Directors; Chair of the Nomination and Governance Committee | 67 | ["Senior executive with over twenty years of experience across healthcare, life sciences and pharmaceuticals","Board member of Waters Corporation since 2018","Board member of Signant Health since 2020","Audit committee chair of Waters Corporation","Board member of Zeus, Inc. and Flourish Research since 2025","Board member of Advarra from 2019 until its sale in 2022","Executive Vice President and Chief Financial Officer of PRA Health Sciences, Inc. from 2007 to 2018","Worked at Pharmaceutical Product Development, Inc. from 1995 to 2007","Earned both a B.A. and M.B.A. from the University of North Carolina at Wilmington","CPA-retired","audit committee financial expert"] | ["Nomination and Governance Committee","Audit Committee","Compensation Committee","Nomination & Governance Committee"] | 2026 |
Companies shown below are based on exact name match for the selected Director
| Ticker | Position | Age | Qualifications and Experience | Committee Memberships | Filing Year |
|---|---|---|---|---|---|
| WAT | Independent Director | 67 | ["Significant accounting, finance and health care industry expertise","Extensive experience as a senior financial executive across healthcare, life sciences, and pharmaceutical services and banking companies","Oversaw the financial strategy of PRA Health Sciences","Deep familiarity with all aspects of life science industry financial reporting, accounting, compliance and risk management","Retired Certified Public Accountant","EVP and CFO at PRA Health Sciences (2007 – 2018)","CFO and Accounting Officer at Pharmaceutical Product Development, Inc. (2002 – 2007)","Chief Accounting Officer at Pharmaceutical Product Development, Inc. (1997 – 2007)","Corporate Controller at Pharmaceutical Product Development, Inc. (1995 – 1997)","Controller at Cooperative Bank for Savings Inc. (1980 – 1995)","BA and MBA, University of North Carolina at Wilmington"] | ["Audit & Finance"] | 2026 |
Biography sourced from the proxy statement filing.
Linda Baddour, age 67, became a member of our Board of Directors in March 2021 and serves as Chair of the Nomination and Governance Committee, Chair of the Audit Committee and member of the Compensation Committee of our Board of Directors. Ms. Baddour is an experienced senior executive with over twenty years of experience across healthcare, life sciences and pharmaceuticals. Ms. Baddour has served on the board of directors of Waters Corporation (NYSE: WAT), a publicly traded analytical laboratory instrument and software company, since 2018, and Signant Health, since 2020. Ms. Baddour is currently serving as the audit committee chair of Waters Corporation. Ms. Baddour has also served on the board of directors of two private companies, Zeus, Inc. and Flourish Research, since 2025. Ms. Baddour also served on the board of directors of Advarra, a Genstar Capital portfolio company, from 2019 until its sale in 2022. From 2007 to 2018, Ms. Baddour served as Executive Vice President and Chief Financial Officer of PRA Health Sciences, Inc., a global contract research organization and data science company. During Ms. Baddour s tenure, PRA Health Sciences grew from approximately 3,000 employees to over 17,000. From 1995 to 2007, Ms. Baddour worked at Pharmaceutical Product Development, Inc., a contract research organization, serving in various roles, including as Chief Financial Officer, Treasurer and Chief Accounting Officer. Ms. Baddour earned both a B.A. and M.B.A. from the University of North Carolina at Wilmington, and is a CPA-retired. We believe Ms. Baddour s financial and business expertise, including her background in global contract research organizations, financial leadership in mergers and acquisitions makes her well-qualified to serve as a member of our Board of Directors.